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                                          INTRODUCTION 
          COPD is a disease of increasing public health importance around  
the world. GOLD estimates suggest that COPD will rise from the sixth to 
the third most common cause of death worldwide by 2020. Worldwide, 
COPD is the only leading cause of death that still has a rising mortality. 
Even though there have been significant advances in the understanding 
and management of COPD, the disease may be largely preventable, but it 
remains marginally treatable. 
            It is well known that COPD is a syndrome of progressive airflow 
limitation caused chronic inflammation of the airways and lung 
parenchyma. But it also produces significant systemic consequences.The 
role of systemic inflammation as evidenced by the rise in inflammatory 
markers is now being increasingly recognised to play an important role in 
the systemic effects. The systemic effects include cachexia, skeletal 
muscle dysfunction, cardiovascular disease, osteoporosis, depression, 
fatigue among many others. 
            It is also found that there is an ongoing hypercoagulable state in 
COPD. It is evidenced by the increased incidence of pulmonary 
thrombosis and coronary artery disease in these patients. The 
hypercoagulable state is being attributed to altered platelet functions and 
clotting system activation as has been shown by increased platelet size, 
high blood fibrinogen levels in patients with COPD. 
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            It is also now recognised that systemic inflammation could 
contribute to the declining lung function and also to the increased number 
of acute exacerbations as shown by recent reports. Existing therapies for 
COPD are grossly inadequate. None has been shown to slow the 
relentless progression of the disease. Therefore the current direction is 
regarding the attenuation of systemic inflammation which may offer new 
perspectives in the management of COPD. New molecules to counteract 
the underlying inflammation and destruction of this relentlessly 
progressive chronic debilitating disease are desired. 
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REVIEW OF LITERATURE 
                                                   COPD  
          Chronic obstructive pulmonary disease (COPD) has been defined 
by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), 
an international collaborative effort to improve awareness, diagnosis, and 
treatment of COPD, as a disease state characterized by airflow limitation 
that is not fully reversible. COPD includes emphysema, an anatomically 
defined condition characterized by destruction and enlargement of the 
lung alveoli; chronic bronchitis, a clinically defined condition with 
chronic cough and phlegm; and small airways disease, a condition in 
which small bronchioles are narrowed.1 
RISK FACTORS:- 
CIGARETTE SMOKING 
          Longitudinal studies have shown accelerated decline in the volume 
of air exhaled within the first second of the forced expiratory maneuver 
(FEV1) in a dose-response relationship to the intensity of cigarette 
smoking, which is typically expressed as pack-years (average number of 
packs of cigarettes smoked per day multiplied by the total number of 
years of smoking). The historically higher rate of smoking among males 
is the likely explanation for the higher prevalence of COPD among 
males.1 
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          However, only 10–20% of smokers develop clinically significant 
COPD.3  Pipe and cigar smokers have higher morbidity and mortality rates for 
COPD than non-smokers, although their rates are lower than cigarette 
smokers.4  The BTS guidelines suggest that most patients with COPD have at 
least a 20 pack-year smoking history.5 
             In non-smokers the FEV1 begins to decline at 30–35 years of 
age, and this may occur earlier in smokers.6 Although pack-years of 
cigarette smoking is the most highly significant predictor of FEV1 , only 
15% of the variability in FEV1 is explained by pack-years. This  finding 
suggests that additional environmental and/or genetic factors contribute to 
the impact of smoking on the development of airflow obstruction.1 
RESPIRATORY INFECTIONS:- 
          Although respiratory infections are important causes of 
exacerbations of COPD, the association of both adult and childhood 
respiratory infections to the development  of COPD remains to be 
proven.¹ One study in Salt Lake City did find an association between 
lower respiratory tract infection and an accelerated decline in FEV1, but 
in a group who already had established COPD.7 
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OCCUPATIONAL EXPOSURES:- 
Although nonsmokers in these occupations developed some 
reductions in FEV1, the importance of dust exposure as a risk factor for 
COPD, independent of cigarette smoking, is not certain. 1 
 AMBIENT AIR POLLUTION:- 
          The relationship of air pollution to chronic airflow obstruction 
remains unproven. Prolonged exposure to smoke produced by biomass 
combustion—a common mode of cooking in some countries—also 
appears to be a significant risk factor for COPD among women in those 
countries.1  
PASSIVE, OR SECOND-HAND, SMOKING EXPOSURE:- 
         In utero tobacco smoke exposure also contributes to significant 
reductions in postnatal pulmonary function. Although passive smoke 
exposure has been associated with reductions in pulmonary function, the 
importance of this risk factor in the development of the severe pulmonary 
function reductions in COPD remains uncertain.1 
AIRWAY RESPONSIVENESS AND COPD:- 
           A tendency for increased bronchoconstriction in response to a 
variety of exogenous stimuli is one of the defining features of asthma. 
However, many patients with COPD also share this feature of airway 
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hyperresponsiveness. Airway hyperresponsiveness is a risk factor for 
COPD.1 
GENETIC CONSIDERATIONS:- 
          Severe α1 antitrypsin (α1AT) deficiency is a proven genetic risk 
factor for COPD; there is increasing evidence that other genetic 
determinants also exist.1 
 NATURAL HISTORY:- 
             The effects of cigarette smoking on pulmonary function appear to 
depend on the intensity of smoking exposure, the timing of smoking 
exposure during growth, and the baseline lung function of the individual; 
other environmental factors may have similar effects. Although rare 
individuals may demonstrate precipitous declines in pulmonary function, 
most individuals follow a steady trajectory of increasing pulmonary 
function with growth during childhood and adolescence, followed by a 
gradual decline with aging.  
              Individuals appear to track in their quartile of pulmonary 
function based upon environmental and genetic factors that put them on 
different tracks. The risk of eventual mortality from COPD is closely 
associated with reduced levels of FEV1. Smoking cessation at an earlier 
age provides a more beneficial effect than smoking cessation after 
marked reductions in pulmonary function have already developed. Rate 
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of decline of FEV1 increases with increasing numbers of cigarettes 
smoked.1 
               The strongest predictors of survival in patients with COPD are 
age and baseline FEV1.8 Less than 50% of patients whose FEV1 has 
fallen to 30% of predicted are alive 5 years later .9 Other unfavourable 
prognostic factors include severe hypoxaemia, a high pulmonary arterial 
pressure and low DLCo, which become apparent in patients with severe 
disease.4,9 The factors that favour improved survival are stopping 
smoking and a large response to bronchodilator.2  
 
 EFFECTS OF SMOKING CESSATION:- 
                After smoking cessation these subjects have a rate of decline in 
FEV1 that approaches that found in people who have never smoked.10  
Short-term studies of stopping smoking have shown improvement in 
small airway tests, such as the single-breath nitrogen test, although 
changes in maximum expiratory flow–volume curves have been 
variable.11 However, a clear improvement in survival has been 
demonstrated in exsmokers with advanced disease .8 
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PATHOPHYSIOLOGY:- 
AIRFLOW OBSTRUCTION:- 
               Airflow limitation, also known as airflow obstruction, is 
typically determined by spirometry, which involves forced expiratory 
maneuvers after the subject has inhaled to total lung capacity . Key 
phenotypes obtained from spirometry include FEV1 and the total volume 
of air exhaled during the entire spirometric maneuver (FVC). Patients 
with airflow obstruction related to COPD have a chronically reduced ratio 
of FEV1/FVC. In contrast to asthma, the reduced FEV1 in COPD seldom 
shows large responses to inhaled bronchodilators, although improvements 
up to 15% are common. 
               In normal lungs, as well as in lungs affected by COPD, maximal 
expiratory flow diminishes as the lungs empty because the lung 
parenchyma provides progressively less elastic recoil and because the 
cross-sectional area of the airways falls, raising the resistance to airflow. 
The decrease in flow coincident with decreased lung volume is readily 
apparent on the expiratory limb of a flow-volume curve. In the early 
stages of COPD, the abnormality in airflow is only evident at lung 
volumes at or below the functional residual capacity (closer to residual 
volume), appearing as a scooped-out lower part of the descending limb of 
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the flow-volume curve. In more advanced disease the entire curve has 
decreased expiratory flow compared to normal.1 
HYPERINFLATION :- 
              In COPD there is "air trapping" (increased residual volume and 
increased ratio of residual volume to total lung capacity) and progressive 
hyperinflation (increased total lung capacity) late in the disease.1  
GAS EXCHANGE:- 
                 Although there is considerable variability in the relationships 
between the FEV1 and other physiologic abnormalities in COPD, certain 
generalizations may be made. The PaO2 usually remains near normal until 
the FEV1 is decreased to ~50% of predicted, and even much lower FEV1s 
can be associated with a normal PaO2, at least at rest. An elevation of 
PaCO2 is not expected until the FEV1 is <25% of predicted and even then 
may not occur. Pulmonary hypertension severe enough to cause cor 
pulmonale and right ventricular failure due to COPD occurs only in those 
individuals who have marked decreases in FEV1 (<25% of predicted) 
together with chronic hypoxemia (PaO2 <55 mmHg), although earlier in 
the course some elevation of pulmonary artery pressure, particularly with 
exercise, may occur.1 
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PATHOGENESIS:-  
ELASTASE & ANTIELASTASE HYPOTHESIS:-  
               This hypothesis was based on the clinical observation that 
patients with genetic deficiency in α1AT, the inhibitor of the neutrophil 
elastase, were at increased risk of emphysema, and that instillation of 
elastases, including neutrophil elastase, to experimental animals results in 
emphysema.  
                Neutrophils sequester in the pulmonary capillaries initially as a 
result of the oxidant effect of cigarette smoke, which decreases neutrophil 
deformability. Activated neutrophils adhere to the endothelial cells and 
subsequently migrate into the airspaces. Oxidants, either directly from 
cigarette smoke or released from activated airspace neutrophils, inactivate  
antiproteases such as alpha -1 antitrypsin, reducing its ability to bind to 
and hence inactivate proteases, particularly elastase. This allows active 
elastase to enter the lung interstitium and bind to and destroy elastin, 
causing destruction and enlargement of the distal airspace walls. 2 
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DECREASED ANTIPROTEASE FUNCTION:- 
             A critical event in the protease–antiprotease theory of the 
pathogenesis of emphysema is the concept of a functional deficiency of 
alpha-1antitrypsin in the airspaces produced by smoking due to oxidation 
of the methionine-358 residue at the active site of the alpha-1AT 
molecule. This can occur by a direct oxidative effect of cigarette smoke 
or by oxidants released from activated airspace leucocytes.12  
INFLAMMATION AND EXTRACELLULAR MATRIX 
PROTEOLYSIS :- 
              Macrophages patrol the lower airspace under normal conditions. 
Upon exposure to oxidants from cigarette smoke, histone deacetylase-2 is 
inactivated, shifting the balance toward acetylated or loose chromatin, 
exposing nuclear factor κB sites and resulting in transcription of matrix 
metalloproteinase-9, proinflammatory cytokines interleukin 8 (IL-8), and 
tumor necrosis factor α (TNF-α); this leads to neutrophil recruitment. 
Matrix metalloproteinases and serine proteinases, most notably neutrophil 
elastase, work together by degrading the inhibitor of the other, leading to 
lung destruction. Proteolytic cleavage products of elastin also serve as a 
macrophage chemokine, fueling this destructive positive feedback loop. 
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            Surprisingly, in end-stage lung disease, long after smoking 
cessation there remains an exuberant inflammatory response, suggesting 
that  mechanisms of cigarette smoke-induced inflammation that initiate 
the disease differ from mechanisms that sustain inflammation after 
smoking cessation. 1 
COPD AS A SYSTEMIC DISEASE:- 
 
            Although the traditional paradigm is that patients with COPD die 
predominantly from progressive respiratory failure, large clinical studies 
have demonstrated that the leading cause of mortality in the overall 
COPD population (regardless of severity) is ischemic heart disease.13,14  
             Many population-based studies have evaluated the effect of 
reduced lung function on cardiovascular morbidity and mortality.13,14 
Although there is some heterogeneity of results across the studies, they 
uniformly demonstrate that reduced FEV1 increases the risk of 
cardiovascular mortality by approximately two-fold relative to those with 
normal (or preserved) FEV1 values, even after taking into account 
smoking history. Even among nonsmokers, reduced FEV1 is a powerful 
risk factor for poor cardiovascular outcomes.14 Indeed, FEV1 may be as 
important as cholesterol is in predicting cardiovascular mortality in the 
general population.14 According to the Lung Health Study, a 10% 
decrement in FEV1 among COPD patients is associated with an 
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approximate 30% increase in the risk of deaths from cardiovascular 
diseases.14 Reduced FEV1 is also an important independent risk factor for 
thromboembolic disease, sudden death, arrhythmias, heart failure, and 
stroke.15 Other systemic effects include cachexia, skeletal muscle 
dysfunction, cardiovascular disease, osteoporosis, depression, fatigue 
among many others. Polycythemia is uncommon in COPD, occurring in 
5% of patients, and is not associated with greater hypoxemia or any other 
important clinical expression of the disease.44 
SYSTEMIC INFLAMMATION IN COPD: 
           There is growing evidence that persistent low-grade systemic 
inflammation is present in COPD and that this may contribute to the 
pathogenesis of atherosclerosis and cardiovascular disease among COPD 
patients.16  
            In COPD patients, the nidus for the low-grade systemic 
inflammation is likely the airways. There are compelling data to indicate 
the existence of prominent inflammation in the small airways of COPD 
patients. The severity of the inflammation corresponds to the severity of 
airflow obstruction and patient symptoms.17 There are also inflammatory 
changes within pulmonary vessels and alveolar tissues.17 Cigarette smoke 
and other noxious environmental agents, which are causative factors for 
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COPD genesis, directly stimulate alveolar macrophages, bronchial 
epithelial cells, and other cells (like neutrophils) to release various 
proinflammatory cytokines and chemokines.18 Some of these molecules 
have a direct "toxic" effect on tissues, whereas others act as secondary 
messengers to recruit and activate other inflammatory cells to release 
other pro-inflammatory mediators, thereby amplifying the original 
inflammatory signal and promoting tissue damage. Once the pulmonary 
inflammation becomes firmly established, the inflammatory signals may 
then spill over into the general circulation, creating a state of low-grade 
systemic inflammation.16
              Release of inflammatory mediators and activated inflammatory 
cells such as tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) 
into the systemic circulation is  associated with reduced lung function and 
is also believed to play a role in  systemic diseases seen in association 
with COPD. Some systemic inflammatory markers in COPD include 
TNF-α, several interleukins, lipopolysaccharide binding protein, soluble 
TNF-α receptors, leukocytes, and acute phase proteins such as C-reactive 
protein (CRP) and fibrinogen.19,20,21 
            There may be other pathways by which COPD patients may 
experience poor cardiovascular outcomes. Heindl et al.22 demonstrated 
that patients with chronic respiratory failure and hypoxia had elevated 
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sympathetic nervous activity compared with the control population. 
Interestingly, in their study, correction of hypoxia with supplemental 
oxygen therapy attenuated, but did not normalize, the sympathetic 
nervous activity of these patients, suggesting the potential role of other 
factors in this process. Administration of ß-2 adrenergic or 
anticholinergic bronchodilators may further increase the sympathetic 
nervous activity of COPD patients and thereby amplify their risk for poor 
cardiovascular events.23  Indeed, epidemiologic studies and clinical trials 
have shown that these medications may increase the risk of 
cardiovascular morbidity and mortality by ~50%-100%.24,25,26
           Increased systemic inflammation is also a risk factor COPD 
exacerbations.  Elevated fibrinogen levels is an independent risk factor 
for exacerbations of COPD. 21 In COPD, airway and systemic 
inflammation markers increase over time. High levels of these markers 
are associated with a faster decline in lung function.27  
           Fibrinogen in the lungs can (i) inactivate pulmonary surfactant, 
causing increased surface-tension relationships in the distal airways, (ii) 
promote the expression of molecules that induces airway fibrosis and 
narrowing, and (iii) activate plasminogen activator inhibitor type-1 
leading to excess fibrin deposition in the airways and airway narrowing. 
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These properties of fibrinogen suggest that it is more than an 
epiphenomenon; rather it is involved in the causal pathways.28 
              There are other studies which show that chronic obstructive 
airway disease patients have altered platelet functions and clotting system 
activation.29,30  In particular, it has been shown that there is a shortened 
platelet  half life, increased platelet size, increased platelet aggregation, 
high levels of blood fibrinogen and in vitro and in vivo platelet activation 
in these patients. Increased size of the platelets could be because of  
hypoxia causing bone marrow stimulation resulting in secretion of larger 
platelets, or it could be because of increased sequestration of smaller 
platelets with larger platelets remaining in circulation. Larger the 
platelets, more is the platelet activity resulting in increased platelet 
aggregation and release of active mediators which can cause endothelial 
cell injury.29,30 Thrombopoiesis may be stimulated by IL-6 as a result of 
systemic inflammation.31 In COPD  patients there is a negative 
correlation between MPV and PaO2.32 There is also lower ATIII  in 
addition to higher platelet mass and fibrinogen.33 
PULMONARY CIRCULATION:- 
          Among the earliest changes in the pulmonary vasculature that 
develop as airflow limitation worsens is thickening of the intima of the 
small pulmonary arteries .34 Medial hypertrophy then develops in the 
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muscular pulmonary arteries in those patients who develop pulmonary 
arterial hypertension . Peripheral airway inflammation in patients with 
COPD may be associated with pulmonary arterial thrombosis .35
         When chronic hypoxaemia develops, the consequent pulmonary 
arterial hypertension is associated with right ventricular hypertrophy. 
 CLINICAL FEATURES: 
           The  characteristic symptoms of COPD are breathlessness on 
exertion, sometimes accompanied by wheeze and cough, which is often 
but not invariably productive.  Most patients have a smoking history of at 
least 20 packyears before symptoms develop, commonly in the fifth 
decade.  However, when the FEV1 has fallen to 30% or less of the 
predicted values (equivalent in an average man to an FEV1 of around 
1L), breathlessness is usually present on minimal exertion . Wheeze is 
common but not specific to COPD.2 
            Psychiatric morbidity, particularly depression, is common in 
patients with severe COPD, reflecting the social isolation and the 
chronicity of the disease. Sleep quality is impaired in advanced COPD , 
which may contribute to the impaired neuropsychiatric performance. 
           In the early stages of COPD, patients usually have an entirely 
normal physical examination. In patients with more severe disease, the 
physical examination is notable for a prolonged expiratory phase and 
expiratory wheezing. In addition, signs of hyperinflation include a barrel 
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chest and enlarged lung volumes with poor diaphragmatic excursion as 
assessed by percussion.  
         Advanced disease may be accompanied by systemic wasting, with 
significant weight loss, bitemporal wasting, and diffuse loss of 
subcutaneous adipose tissue. This syndrome has been associated with      
both inadequate oral intake and elevated levels of inflammatory cytokines 
(TNF-α). Such wasting is an independent poor prognostic factor in 
COPD.1 
 
CLASSIFICATION OF COPD: 1    
 Gold Criteria for COPD Severity  
GOLD 
Stage 
Severity Symptoms Spirometry 
0  At Risk Chronic cough, sputum 
production 
Normal 
I Mild With or without chronic 
cough or sputum production 
FEV1/FVC<0.7and                   
FEV1≥80%predicted 
  
II Moderate With or without chronic 
cough or sputum production 
FEV1/FVC <0.7 and 
 50%≤FEV1<80%predicted 
  
III Severe With or without chronic 
cough or sputum production 
FEV1/FVC <0.7 and 
 30%≤FEV1<50%predicted 
  
IV Very 
Severe 
With or without chronic 
cough or sputum production 
FEV1/FVC <0.7 and FEV1 <30% 
predicted 
or 
FEV1 <50% predicted with 
respiratory failure or signs of right 
heart failure  
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CHRONIC OBSTRUCTIVE PULMONARY DISEASE: TREATMENT 
STABLE PHASE COPD:- 
     Only three interventions—smoking cessation, oxygen therapy in 
chronically hypoxemic patients, and lung volume reduction surgery in 
selected patients with emphysema—have been demonstrated to influence 
the natural history of patients with COPD. 1 
PHARMACOTHERAPY:- 
SMOKING CESSATION:- 
  It has been shown that middle-aged smokers who were able to 
successfully stop smoking experienced a significant improvement in the 
rate of decline in pulmonary function, returning to annual changes similar 
to that of nonsmoking patients. There are two principal pharmacologic 
approaches to the problem: bupropion, originally developed as an 
antidepressant medication, and nicotine replacement therapy. The latter is 
available as gum, transdermal patches, inhaler, and nasal spray.1 
BRONCHODILATORS:- 
          In general, bronchodilators are used for symptomatic benefit in 
patients with COPD. The inhaled route is preferred for medication 
delivery as the incidence of side effects is lower than that seen with the 
use of parenteral medication delivery.1 
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ANTICHOLINERGIC AGENTS:- 
          While regular use of ipratopium bromide does not appear to 
influence the rate of decline of lung function, it improves symptoms and 
produces acute improvement in FEV1. Tiotropium, a long-acting 
anticholinergic, has been shown to improve symptoms and reduce 
exacerbations. 1 
BETA AGONISTS:- 
          These provide symptomatic benefit.Long-acting inhaled β agonists, 
such as salmeterol, have benefits comparable to ipratopium bromide. 
Their use is more convenient than short-acting agents. The addition of a β 
agonist to inhaled anticholinergic therapy has been demonstrated to 
provide incremental benefit.¹ 
INHALED CORTICOSTEROIDS:- 
          Inhaled glucocorticoids reduce exacerbation frequency by ~25%. A 
more recent meta-analysis suggests that they may also reduce mortality 
by ~25%. A definitive conclusion regarding the mortality benefits awaits 
the results of ongoing prospective trials. A trial of inhaled glucocorticoids 
should be considered in patients with frequent exacerbations, defined as 
two or more per year, and in patients who demonstrate a significant 
amount of acute reversibility in response to inhaled bronchodilators.¹ 
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ORAL GLUCOCORTICOIDS:-       
          The chronic use of oral glucocorticoids for treatment of COPD is 
not recommended because of an unfavorable benefit/risk ratio.¹ 
THEOPHYLLINE:- 
          Theophylline produces modest improvements in expiratory flow 
rates and vital capacity and a slight improvement in arterial oxygen and 
carbon dioxide levels in patients with moderate to severe COPD. ¹ 
OXYGEN:- 
          Supplemental O2 is the only pharmacologic therapy demonstrated 
to decrease mortality in patients with COPD. For patients with resting 
hypoxemia (resting O2 saturation <88% or <90% with signs of pulmonary 
hypertension or right heart failure), the use of O2 has been demonstrated 
to have a significant impact on mortality. Patients meeting these criteria 
should be on continual oxygen supplementation, as the mortality benefit 
is proportional to the number of hours/day oxygen is used. Various 
delivery systems are available, including portable systems that patients 
may carry to allow mobility outside the home.¹ 
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OTHER AGENTS:- 
         Specific treatment in the form of intravenous α1AT augmentation 
therapy is available for individuals with severe α1AT deficiency. 
Although biochemical efficacy of α1AT augmentation therapy has been 
shown, a randomized controlled trial of α1AT augmentation therapy has 
never proven the efficacy of augmentation therapy in reducing decline of 
pulmonary function. Eligibility for α1AT augmentation therapy requires a 
serum α1AT level <11 µM (approximately 50 mg/dL). Typically, PiZ 
individuals will qualify, although other rare types associated with severe 
deficiency (e.g., null-null) are also eligible. Since only a fraction of 
individuals with severe α1AT deficiency will develop COPD, α1AT 
augmentation therapy is not recommended for severely α1AT-deficient 
persons with normal pulmonary function and a normal chest CT scan. ¹ 
NONPHARMACOLOGIC THERAPIES:- 
GENERAL MEDICAL CARE:- 
          Patients with COPD should receive the influenza vaccine annually. 
Polyvalent pneumococcal vaccine is also recommended, although proof 
of efficacy in this patient population is not definitive. 
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PULMONARY REHABILITATION:-   
        This refers to a treatment program that incorporates education and 
cardiovascular conditioning. In COPD, pulmonary rehabilitation has been 
demonstrated to improve health-related quality of life, dyspnea, and 
exercise capacity. It has also been shown to reduce rates of  
hospitalization over a 6–12-month period. 
LUNG VOLUME REDUCTION SURGERY (LVRS):- 
        Patients are excluded if they have significant pleural disease, a 
pulmonary artery systolic pressure >45 mmHg, extreme deconditioning, 
congestive heart failure, or other severe comorbid conditions. Recent data 
demonstrate that patients with an FEV1 <20% of predicted and either 
diffusely distributed emphysema on CT scan or DLCO <20% of predicted 
have an increased mortality after the procedure and thus are not  
candidates for LVRS. 
LUNG TRANSPLANTATION :- 
        Current recommendations are that candidates for lung 
transplantation should be <65 years; have severe disability despite 
maximal medical therapy; and be free of comorbid conditions such as 
liver, renal, or cardiac disease.¹ 
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EXACERBATIONS OF COPD:-                       
Exacerbations are commonly considered to be episodes of 
increased dyspnea and cough and change in the amount and character of 
sputum. The frequency of exacerbations increases as airflow obstruction 
increases; patients with moderate to severe airflow obstruction [GOLD 
stages III,IV] have 1–3 episodes per year. 
PRECIPITATING CAUSES AND STRATEGIES TO REDUCE 
FREQUENCY OF EXACERBATIONS:- 
          Bacterial infections play a role in many, but by no means all, 
episodes. Viral respiratory infections are present in approximately one-
third of COPD exacerbations. In a significant minority of instances (20–
35%), no specific precipitant can be identified. Despite the frequent 
implication of bacterial infection, chronic suppressive or "rotating" 
antibiotics are not beneficial in patients with COPD. ¹ 
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TREATMENT OFACUTE EXACERBATIONS:- 
BRONCHODILATORS:-  
          Typically, patients are treated with an inhaled β agonist, often with 
the addition of an anticholinergic agent. Patients are often treated initially 
with nebulized therapy, as such treatment is often easier to administer in 
older patients or to those in respiratory distress. ¹ 
ANTIBIOTICS:-                            
          Bacteria frequently implicated in COPD exacerbations include 
Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella 
catarrhalis. In addition, Mycoplasma pneumoniae or Chlamydia 
pneumoniae are found in 5–10% of exacerbations. The choice of 
antibiotic should be based on local patterns of antibiotic susceptibility of 
the above pathogens as well as the patient's clinical condition.¹  
GLUCOCORTICOIDS:- 
          Among patients admitted to the hospital, the use of glucocorticoids 
has been demonstrated to reduce the length of stay, hasten recovery, and 
reduce the chance of subsequent exacerbation or relapse for a period of 
up to 6 months.One study demonstrated that 2 weeks of glucocorticoid 
therapy produced benefit indistinguishable from 8 weeks of therapy. The 
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GOLD guidelines recommend 30–40 mg of oral prednisolone or its 
equivalent for a period of 10–14 days. ¹ 
OXYGEN:- 
          Supplemental O2 should be supplied to keep arterial saturations  > 
90%. Hypoxic respiratory drive plays a small role in patients with COPD. 
Studies have demonstrated that in patients with both acute and chronic 
hypercarbia, the administration of supplemental O2 does not reduce 
minute ventilation. It does, in some patients, result in modest increases in 
arterial PaCO2, chiefly by altering ventilation-perfusion relationships 
within the lung. This should not deter practitioners from providing the 
oxygen needed to correct hypoxemia.¹ 
MECHANICAL VENTILATORY SUPPORT:- 
            The initiation of noninvasive positive pressure ventilation 
(NIPPV) in patients with respiratory failure, defined as PaCO2 >45 mmHg, 
results in a significant reduction in mortality, need for intubation, 
complications of therapy, and hospital length of stay. Contraindications to 
NIPPV include cardiovascular instability, impaired mental status or 
inability to cooperate, copious secretions or the inability to clear 
secretions, craniofacial abnormalities or trauma precluding effective 
fitting of mask, extreme obesity, or significant burns. 
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            Invasive (conventional) mechanical ventilation via an 
endotracheal tube is indicated for patients with severe respiratory distress 
despite initial therapy, life-threatening hypoxemia, severe hypercapnia 
and/or acidosis, markedly impaired mental status, respiratory arrest, 
hemodynamic instability, or other complications. For patients age >65 
admitted to the intensive care unit for treatment, the mortality doubles 
over the next year to 60%, regardless of whether mechanical ventilation 
was required.¹ 
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                                  AIMS AND OBJECTIVES 
 
The aims of  the study were as follows- 
 
1.To study the plasma fibrinogen level in patients with COPD 
 
 
2.To study the mean platelet volume in patients with COPD 
 
3.To study the correlation between plasma fibrinogen level and mean 
platelet volume and severity of  COPD 
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           MATERIALS AND METHODS 
THE STUDY DESIGN:  CASE CONTROL STUDY 
PERIOD OF STUDY:  JUNE 2008 TO JUNE 2009 
MATERIALS/SELECTION OF STUDY SUBJECTS:  OUTPATIENTS 
AND INPATIENTS VISITING THE MEDICAL AND THORACIC 
MEDICINE DEPARTMENT AND  ON HEALTHY VOLUNTEERING 
CONTROLS. 
ETHICAL CLEARANCE: ETHICAL CLEARANCE OBTAINED 
CONSENT : INFORMED CONSENT    OBTAINED     
FROM CASES AND CONTROLS 
CONFLICT OF INTEREST : NIL 
FINANCIAL SUPPORT: NIL 
FOR CASES:- 
INCLUSION CRITERIA:- 
1. Male patients with Chronic obstructive pulmonary disease 
(FEV1/FVC <70%) 
2. Ex- smokers (who has quit smoking for  > 15 years) 
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EXCLUSION CRITERIA:- 
1. Patients in Acute exacerbation 
2. Bronchial asthma (improvement of FEV1 by >15%after 
bronchodilator suggesting reversibility of airflow obstruction) 
3. Restrictive lung diseases (FVC/FEV1 ≥ 70%; Predicted FEV1% < 
80%)  
4. Pulmonary tuberculosis 
5. Bronchiectasis 
6. Malignancies 
7. Acute infections  
8. Inflammatory disorders (eg.,Rheumatoid arthritis, 
glomerulonephritis) 
9. Cardiac failure 
10. Acute Myocardial infarction , Acute stroke  
11. Significant trauma 
12. Patients refusing consent 
FOR CONTROLS :- 
INCLUSION CRITERIA:- 
1. Males aged > 18 years 
2. Non smokers 
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EXCLUSION CRITERIA:- 
1. Presence of  Systemic illness 
2. Past H/O tuberculosis or respiratory diseases 
3. Presence of  respiratory ailments 
4. Those refusing consent 
METHODS:- 
                A total number of  90 cases and 80 controls were examined out 
of which 75 cases and 75 controls were included in the study as per 
inclusion and exclusion criteria.  
         In the cases group, detailed history was elicited from the 
patients including the number of acute exacerbations (defined as episodes 
of increased dyspnea and cough and change in the amount and character 
of sputum)¹  in the past 12 months and they were classified by spirometric 
measurements of   FEV1/FVC & FEV1% Predicted into four groups – 
stage I, stage II, stage III, and stage IV according to GOLD classification 
of COPD.¹  Routine blood investigations, chest x-ray, were done  and 
their plasma fibrinogen, mean platelet volume, PaO2 were measured. 
Echocardiographic evaluation was also done.  Mean platelet volume was 
measured by  automatic cell analyzer.
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            In the control group, after eliciting detailed history, FEV/FVC, 
FEV1% Predicted were calculated using spirometry. Routine blood 
investigations were done and their plasma fibrinogen, mean platelet 
volume, PaO2 measurements were measured. 
FEV1:- Forced expiratory volume in 1 second (FEV1) is the volume of 
air that can be expelled from maximum inspiration in the first second. 
FVC (Forced vital capacity) :-  The Forced vital capacity (FVC) of the 
lung is the volume of air that can be forcibly expelled from the lung from 
the maximum inspiration to the maximum expiration. 
The FEV1/FVC ratio is the FEV1 expressed as a percentage of the FVC 
is the proportion of the vital capacity inhaled in the first second. It 
distinguishes between reduced FEV1 due to restricted lung volume and 
that due to obstruction. Obstruction is defined as an FEV1/FVC ratio of 
<70% 
FEV1% Predicted :- It is the ratio of  FEV1 to the predicted FEV1 
expressed as percentage. Predicted FEV1is a reference value based on 
age, height, sex, smoking behaviour and race. 
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SPIROMETRIC MEASUREMENTS:- 
The patient is made seated or to stand. It is seen to it that the 
patient is comfortable. All restricting clothing is loosened or removed. 
The noseclip is applied with a tissue. The mouthpiece is placed in the 
mouth, chin slightly elevated, the neck stretched, and the patient is 
allowed to get accustomed to breathing into the apparatus. When the 
patient reaches the end of a normal expiration patient is asked to take a 
slow deep breath. Without the patient making pause at the level of the 
maximum inspiration (total lung capacity), the patient is asked to blow as 
hard and as fast as he can. And while the patient blows out he is 
encouraged to blow longer.   Particularly in patients with obstructive lung 
disease, an effort should be made to extend the expiratory effort to 6 
seconds or more. The trunk and head is kept upright throughout the 
maneuver. The mouthpiece is taken out of the patient’s mouth but the 
noseclip is left attached. The patient is allowed to take rest for a short 
time (15-30s) and explained in what respect the maneuver needs to be 
improved, or reassured if it was properly performed. After a sufficiently 
break the maneuver is repeated.  
          The largest value of three technically satisfactory maneuvers is 
reported. The FVC and the FEV1 reported should not be different by 
more than 150ml from the next largest FVC/ FEV1, or 100ml if the FVC 
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is 1.0 L or less. If the difference is larger upto 8 maneuvers is performed. 
4 puffs of 100µg inhaled salbutamol is administered. Then spirometry is 
repeated 20 minutes after administration of drug. In adults an  increase in 
FEV1% by 12% of the initial value is regarded as a significant 
bronchodilator response which is seen in bronchial asthma. 
 
          The individuals who had FEV1/FVC values less than 70% were 
diagnosed as COPD according to GOLD 2004 guidelines. They were 
staged by their FEV1% Predicted values according to GOLD 
classification of COPD. 
            Ex- smokers (who has quit smoking >15 years) were selected 
because smokers can have elevated fibrinogen level . The elevated  
fibrinogen level takes 15 years to fall  to normal values after smoking 
cessation.36,37,38 So, elevated fibrinogen level in COPD patients who are 
ex- smokers (who has quit smoking >15 years) can be attributed to the 
presence of systemic inflammation as a result of COPD. Also, Plasma 
fibrinogen levels show a dose-dependent increase in smokers.39  If  
patients with severe COPD, tends to decrease their smoking status due to 
increased  breathlessness it would alter the correlation between severity 
of COPD and fibrinogen.  So, ex- smokers (who has quit smoking >15 
years) were selected.                  
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            The information collected regarding all the selected cases and 
controls were recorded in a Master Chart. Data analysis was done with 
the help of computer using SPSS version 13.  Using this software, 
frequencies, percentages, means, standard deviations, ‘p’ values were 
calculated using chi square test, independent t samples test, Pearson’s and 
Spearman’s correlation tests. A ‘p’ value less than 0.05 was taken to 
denote significant relationship. 
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RESULTS AND ANALYSIS OF OBSERVED DATA 
                                          TABLE – 1 
 
STAGES OF COPD 
 
GROUP FREQUENCY PERCENT
FEV1 ≥ 80% 15 20.0
FEV1 79- 
50%
20 26.7
FEV1 49- 
30%
20 26.7
FEV1 < 30% 20 26.7
STUDY 
(COPD) 
GROUP
Total 75 100.0
 
 
The COPD group consisted of 15 patients (20%) in STAGE I, 20 
patients (26.7%)  in STAGE II, 20 patients (26.7%) in STAGE III, 20 
patients  (26.7%) in STAGE IV. 
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                                       FIGURE – 1 
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                                              FIGURE – 2 
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                                                  TABLE - 2 
                                 Group N Mean Std. Deviation 
Std. 
Error 
Mean 
Study (COPD) 
Group 75 56.73 6.141 .709 
AGE OF 
PATIENTS(yrs) 
Control (non- 
COPD) Group 75 56.72 4.831 0.558 
                                             p value : 0.988 
The mean age of the patients in the COPD group was 56.73 years and 
in the control group it was 56.72 years. There was no significant 
difference in age between the two groups. 
 
Figure - 2 shows the distribution of pack years smoked in the COPD 
group. The mean value of pack years smoked was  33.71 years. 
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        FIGURE – 3 
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                                               TABLE - 3 
 Group N Mean Std. Deviation Std. Error Mean 
Study 
(COPD) 
group 
75 49.88 10.4268 1.186
FEV1/FVC 
Control 
(non 
COPD) 
group 
75 87.67 4.035 0.466
                        Significant p value : < 0.001 
The mean FEV1/FVC in COPD group was 49.88% and in the control 
group it was 87.67 %.  
 
Figure – 3 shows the correlation between pack years smoked and the 
stages of COPD. More the no. of pack years smoked, more was the 
severity of COPD.   
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       TABLE - 4 
 Group N Mean Std. Deviation 
Std. Error 
Mean 
Study (COPD) 
Group 75 50.28 21.96 2.536 
FEV1% 
PREDICTED 
Control (non- 
COPD) Group 75 87.87 4.354 0.503 
                           Significant p value : < 0.001 
 
The mean Predicted FEV1% in the COPD group was 50.28%  and in 
the control group it was 87.87%. 
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                                             TABLE - 5 
 Group N Mean Std. Deviation 
Std. Error 
Mean 
Study (COPD) 
Group 75 76.45 15.62 1.804 
PaO2(mmHg) 
Control (non- 
COPD) Group 75 95.03        0.915 0.106 
                            Significant p value : < 0.001 
The mean PaO2 in the COPD group was 76.45mmHg and in the 
control group it was 95.03mmHg. 
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                                               FIGURE – 4 
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                                                       TABLE - 6 
 Group N Mean Std. Deviation 
Std. 
Error 
Mean 
Study 
(COPD) 
Group 
75 414.81 73.950 8.539 
FIBRINOGEN(mg%) 
Control (non- 
COPD) 
Group 
75 275.83 47.032 5.431 
                             Significant  p value : < 0.001  
The mean plasma fibrinogen level in the COPD group was 
414.81mg% and in the control group it was 275.83mg%. Plasma 
fibrinogen level was significantly higher in the COPD group 
compared to the control group. 
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    FIGURE – 5 
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                                                   TABLE - 7 
 Group N Mean Std. Deviation 
Std. 
Error 
Mean 
Study (COPD) 
Group 75 9.61 0.9685 0.1118
MEAN 
PLATELET 
VOLUME (fl) 
Control (non- 
COPD) Group 75 8.24 1.0064 0.1162
                  Significant  p value : < 0.001  
The mean platelet volume (MPV) in the COPD group was 9.61fl and 
in the control group it was 8.24fl. MPV was significantly higher in the 
COPD group. 
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     TABLE - 8 
 Group N Mean Std. Deviation 
Std. Error 
Mean 
Study (COPD) 
Group 75 27.53 5.564 0.642 
ESR(mm/hr) 
Control (non- 
COPD) Group 75 10.56 3.438 0.397 
    Significant  p value : < 0.001  
The mean ESR in the COPD group was 27.53mm/hr and in the 
control group it was 10.56mm/hr. The mean ESR was significantly 
higher in the COPD group than in the control group. 
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    TABLE - 9 
 Group N Mean Std. Deviation 
Std. 
Error 
Mean 
Study (COPD) 
Group 75 2.80 0.40 0.046 
PLATELET 
COUNT(in 
lakhs/cumm) 
Control (non- 
COPD) Group 75 2.57 0.52 0.060 
       Significant  p value : 0.002 
The mean platelet count in the COPD group was 2.80 lakhs/cumm 
and in the control group it was 2.57 lakhs/cumm. The mean platelet 
count was significantly higher in the COPD group than in the control 
group.  
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TABLE – 10 
 Group N Mean Std. Deviation 
Std. 
Error 
Mean 
Study 
(COPD) 
Group 
75 8590.67 1173.14 135.46 
LEUCOCYTE 
COUNT (per 
cumm) Control (non- 
COPD) 
Group 
75 8038.67 1354.56 156.41 
       Significant  p value : 0.008 
The mean leucocyte  count in the COPD group was 8590.67 per 
cumm and in the control group it was 8038.67 per cumm. The mean 
leucocyte  count was significantly higher in the COPD group than in 
the control group.  
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    FIGURE –6 
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 TABLE – 11 
  
MEAN 
PLATELET 
VOLUME 
PREDICTED 
FEV1 (%) 
Pearson 
Correlation 1 -.755
Sig. (2-tailed)  .000
MEAN 
PLATELET 
VOLUME 
N 75 75
Pearson 
Correlation -.755 1
Sig. (2-tailed) .000  
PREDICTED 
FEV1 (%) 
N 75 75
 
The correlation between mean platelet volume and predicted FEV1% 
was r = - 0.755. There was significant negative correlation between 
mean platelet volume and predicted FEV1%. 
Figure - 6 shows the relationship between mean platelet volume and 
severity of COPD. As the severity of COPD increased, the mean 
platelet volume increased. 
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                                       TABLE – 12 
  
MEAN 
PLATELET 
VOLUME 
PARTIAL 
PRESSURE OF 
O2 
Pearson 
Correlation 1 -.880
Sig. (2-tailed)  .000
MEAN 
PLATELET 
VOLUME 
N 75 75
Pearson 
Correlation -.880 1
Sig. (2-tailed) .000  
PARTIAL 
PRESSURE OF 
O2 
N 75 75
 
The correlation between mean platelet volume and PaO2 was r =            
- 0.880. There was significant negative correlation between mean 
platelet volume and PaO2. 
 
 
                                     
60 
 
                                            FIGURE –7 
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                                               TABLE – 13 
  FIBRINOGEN PREDICTED FEV1 (%) 
Pearson 
Correlation 1 -.754
Sig. (2-tailed)  .000FIBRINOGEN 
N 75 75
Pearson 
Correlation -.754 1
Sig. (2-tailed) .000  
PREDICTED 
FEV1 (%) 
N 75 75
 
The correlation between fibrinogen and predicted FEV1% was r =           
-0.754. There was significant negative correlation between fibrinogen 
and predicted FEV1%. 
Figure - 7 shows the relationship between plasma fibrinogen and 
stages of COPD. As the stages of COPD increased, the plasma 
fibrinogen value increased.   
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      FIGURE – 8 
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                                                TABLE - 14 
 EXACERBATION 
FIBRIN
OGEN 
correlation 
coefficient 
1.000 .708 
sig. (2-tailed)  .000 
EXACER
BATION 
N 75 75 
correlation 
coefficient 
.708 1.000 
sig. (2-tailed) .000  
Spearman's 
rho 
FIBRINO
GEN 
N 75 75 
 
The correlation between no. of acute exacerbations in the last 12 
months  and fibrinogen was r = 0.708. There was significant positive 
correlation between plasma fibrinogen and no. of acute exacerbations 
in the last 12 months. 
Figure - 8 shows the relationship between plasma fibrinogen and the 
no. of exacerbations (in the past 12 months). As the plasma 
fibrinogen, increased the no. of exacerbations increased. 
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                                        FIGURE -9 
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                                             TABLE – 15 
 
 PREDICTED 
FEV1 (%)
   
PLATELET 
       COUNT  
Pearson 
Correlation
1 -.712
Sig. (2-tailed)  .000
PREDICTED 
FEV1 (%)
N 75 75
Pearson 
Correlation
-.712 1
Sig. (2-tailed) .000  
PLATELET 
COUNT
N 75 75
 
 
 
The correlation between platelet count and FEV1% was  r = - 0.712. 
There was significant negative correlation between platelet count and 
FEV1%. 
 
Figure - 9 shows the correlation between stages of COPD and platelet 
count. As the stage of COPD increased the platelet count increased. 
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                                         TABLE - 16                                            
 
LEUCOCYTE 
COUNT
PREDICTED 
FEV1%
Pearson 
Correlation
1 -.173
Sig. (2-tailed)  .138
PREDICTED 
FEV1 (%)
N 75 75
Pearson 
Correlation
-.173 1
Sig. (2-tailed) .138  
LEUCO 
CYTE 
COUNT
N 75 75
 
The  correlation between leucocyte count and predicted FEV1% was 
- 0.173. There was no significant correlation between leucocyte count 
and predicted FEV1%.  
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                                           DISCUSSION 
COPD  is now widely recognised as systemic disease. Once the 
pulmonary inflammation becomes firmly established, the inflammatory 
signals may then spill over into the general circulation, creating a state of 
low-grade systemic inflammation.16  There is growing evidence that 
persistent low-grade systemic inflammation is present in COPD and that 
this may contribute to the pathogenesis of atherosclerosis and 
cardiovascular disease among COPD patients.16 Other systemic effects 
include cachexia, skeletal muscle dysfunction, cardiovascular disease, 
osteoporosis, depression, fatigue among many others. Also, systemic 
inflammation can also cause decline in lung function.28 Some systemic 
inflammatory markers COPD include TNF-α, several interleukins, 
lipopolysaccharide binding protein, soluble TNF-α receptors, leukocytes, 
and acute phase proteins such as C-reactive protein (CRP) and 
fibrinogen.19,20,21 
          An integral component of the systemic inflammatory response is 
stimulation of the hematopoietic system, specifically the bone marrow,  
that results in the release of leukocytes and platelets into the 
circulation.      
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          There is a shortened platelet  half life, increased platelet size, 
increased platelet aggregation, high levels of blood fibrinogen and in 
vitro and in vivo platelet activation in these patients.40  This may 
contribute to the existing prothrombotic state.
                 Even long after smoking cessation there remains an exuberant 
inflammatory response, suggesting that  mechanisms of cigarette smoke-
induced inflammation that initiate the disease differ from mechanisms 
that sustain inflammation after smoking cessation.1 If COPD patients 
continue to smoke it would add to the airway and systemic inflammation.  
          This study was mainly done to assess the presence of systemic 
inflammation in patients with COPD long after smoking cessation. 
Plasma fibrinogen and mean platelet volume were used as markers of the 
systemic inflammatory and prothrombotic state. In our study, 75 COPD 
patients were compared with 75 age matched controls. 
          The COPD group consisted of 15 patients (20%) in stage I, 20 
patients (26.7%)  in stage II, 20 patients (26.7%) in stage III, 20 patients  
(26.7%) in stage IV. 
          The mean age of the patients in the COPD group was 56.73 years 
and in the control group it was 56.72 years. There was no significant 
difference in age between the two groups. The mean value of pack years 
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smoked was  33.71 years. More the no. of pack years smoked, more was 
the severity of COPD.  The mean FEV1/FVC% in the COPD group and 
in the control group was 49.88% and 87.67% respectively. The mean 
Predicted FEV1% in the COPD group was 50.28% and in the control 
group it was 87.87%. The mean PaO2 in the COPD group was 
76.45mmHg and in the control group it was 95.03mmHg. 
          The results correlated well with the worldwide studies. The study 
by A.Lekka et al33 was performed on 56 COPD patients and 56 age 
matched controls. It showed significantly higher fibrinogen level in 
COPD  patients than in controls (p =0.001).In our study, the mean plasma 
fibrinogen level in the COPD group was 414.81mg% and in the control 
group it was 275.83mg%. The plasma fibrinogen was significantly 
elevated compared to controls (p value <0.001) similarly to their study.  
          The study by Rajeev Bansal et al40 was done in 100 COPD 
patients and 100 normal patients. The mean FEV1/FVC in the COPD and 
in the control group was 52.2% and 90.7% respectively. The mean PaO2 
in the COPD and in the control group was 70.8mmHg and 
90mmHgrespectively. They reported that the mean platelet volume was 
significantly higher in COPD patients than in normal patients (10.8 fl in 
COPD patients compared to 7.96 in normal patients; p = <0.05). In our 
study, the mean platelet volume (MPV) in the COPD group was 9.61fl 
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and in the control group it was 8.24fl. The mean platelet volume was 
significantly higher in COPD patients than in controls (p = <0.001)which 
correlates with their study. 
          In the study by JA Wadachia et al32  mean platelet volume was 
estimated in 35 patients with chronic airflow obstruction and a wide 
range of arterial oxygen tension (PaO2) and they were compared with 18 
normal patients. They found a significant negative correlation (r = -0.70) 
between mean platelet volume and PaO2. In  Our study also there is 
significant negative correlation (r = - 0.88) between mean platelet volume 
and PaO2 which correlates well with this study.  
          Thrombopoiesis may be stimulated by IL-6 as a result of systemic 
inflammation.31   Increased size of the platelets could be also because of  
hypoxia causing bone marrow stimulation resulting in secretion of larger 
platelets. Larger the platelets, more is the platelet activity resulting in 
increased platelet aggregation and release of active mediators which can 
cause endothelial cell injury.29,30 So, as there is increased mean platelet 
volume in COPD patients, it is a prothrombotic state.                  
            The study by  Groenewegen KH et al 21 was done in a group of 
314patients with 277 person years of follow up. They showed that higher 
initial fibrinogen level and a lower FEV1 predicted a higher rate of both 
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moderate and severe exacerbations. They concluded that  elevated 
fibrinogen levels is an independent risk factor for exacerbations of COPD. 
In our study also the number of acute exacerbations in the preceding 12 
months period significantly correlated with fibrinogen level (r = 0.708). 
              The study by G.C.Donaldson et al27 had concluded that  in 
COPD, airway and systemic inflammatory markers increase over time. 
High levels of these markers are associated  with a faster decline in lung 
function. Our study was designed to assess the association between 
plasma fibrinogen, a systemic inflammatory marker, and the severity of 
COPD. Mean platelet volume and its association with severity of COPD 
was also assessed.    
              It was found that there is a significant negative correlation 
between fibrinogen and predicted FEV1% (r = - 0.754) and also between 
mean platelet volume and predicted FEV1% (r = - 0.755). So, it can be 
concluded that as the severity of COPD increases, fibrinogen and mean 
platelet volume increases. 
  The mean platelet count in the COPD group was 2.80lakhs/cumm 
and in the control group it was 2.57lakhs/cumm. The mean platelet count 
was significantly higher in the COPD group than in the control group (p = 
0.002) in our study.  
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             The study by Gulfidan Cakmak et al45 concluded that platelet 
count increased as the severity of COPD increased (p = <0.0001). In our 
study also the platelet count increased as the severity of COPD increased 
(r =    - 0.712). Hence, platelet count can also be taken as an indicator of  
systemic inflammation in COPD. 
The mean leucocyte  count in the COPD group was 8590.67 per 
cumm and in the control group it was 8038.67 per cumm. The mean 
leucocyte  count was significantly higher in the COPD group than in the 
control group (p = 0.008) .  
  The observation in our study that COPD patients had significantly 
elevated leucocyte and platelet count than the controls supports the 
presence of systemic inflammation. However the leucocyte count did not 
significantly correlated with the severity of COPD ( r = - 0.173).  
  The mean ESR in the COPD group was 27.53mm/hr and in the 
control group it was 10.56mm/hr. The mean ESR was significantly higher 
in the COPD group than in the control group (p = <0.001). 
        Research is already underway to target the pulmonary and systemic 
inflammation. Roflumilast, a phosphodiesterase – 4 inhibitor is one 
73 
 
promising drug that addresses both pulmonary and systemic 
inflammation. 41,42,43   
Further research aimed at controlling the systemic inflammation 
would benefit the patients with COPD which until now  remains only 
marginally treatable . 
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SUMMARY 
  The study “Plasma Fibrinogen and Platelet Mass as Indicators of 
the Systemic Inflammatory and Prothrombotic state in COPD” was a case 
control study conducted on 75 COPD patients and 75 healthy controls in 
Govt. Rajaji Hospital, Madurai. 
          Patients and controls who satisfied the inclusion criteria were 
included in the study and detailed history was elicited from them. They 
underwent investigations like, lung function tests, plasma fibrinogen, 
mean platelet volume, PaO2 measurements. 
          COPD patients were found to have significantly elevated plasma  
fibrinogen and mean platelet volume. Plasma fibrinogen and mean 
platelet volume  significantly correlated with severity of COPD. Also, 
they had significantly elevated ESR, leucocyte count and platelet count. 
Platelet count significantly correlated with the severity of COPD.     
          Hence, it can be concluded that there is systemic inflammatory 
prothrombotic state in COPD. Also, the systemic inflammation increases 
with the severity of COPD. 
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                                               CONCLUSION  
1. There is an increased Fibrinogen level in patients with COPD. 
2. There is an increased Mean Platelet Volume in patients with 
COPD. 
3. Fibrinogen and Mean Platelet Volume increases as the severity of 
COPD increases. 
4. There is also an increased leucocyte count, platelet count, ESR in 
patients with COPD. 
5. This indicates that there is Systemic Inflammatory and 
Prothrombotic  state  in COPD. 
6. Systemic Inflammation increases as the severity of COPD 
increases. 
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PAST HISTORY: 
 
SYSTEMIC ILLNESS: 
 
DRUG INTAKE: 
 
PERSONAL HISTORY: 
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NUTRITIONAL STATUS:   ORAL HYGEINE: 
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